Search research articles
Contact Us
Filters
Showing results (11-20 of 66) with videos related to
Page
of 7
Sort By:
Journal of Child and Adolescent Psychopharmacology
|
December 20, 2013
An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder
Justine M Kent, David Hough, Jaskaran Singh, et al.
The Journal of Clinical Psychiatry
|
June 21, 2018
Relapse After Antipsychotic Discontinuation in Schizophrenia as a Withdrawal Phenomenon vs Illness Recurrence: A Post Hoc Analysis of a Randomized Placebo-Controlled Study
Robin Emsley, Isaac Nuamah, Srihari Gopal, et al.
Schizophrenia Research
|
December 5, 2009
Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study
David Hough, Srihari Gopal, Ujjwala Vijapurkar, et al.
Schizophrenia Research. Cognition
|
March 11, 2020
Cognitive functioning in adolescents with schizophrenia treated with paliperidone extended-release: 6-Month exploratory analysis from an open-label, single-arm safety study
Gahan Pandina, Isaac Nuamah, Timothy Petersen, et al.
Neuropsychiatric Disease and Treatment
|
October 5, 2013
Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies
Srihari Gopal, Yanning Liu, Larry Alphs, et al.
Journal of Child and Adolescent Psychopharmacology
|
July 29, 2015
Long-Term Safety of Paliperidone Extended Release in Adolescents with Schizophrenia: An Open-Label, Flexible Dose Study
Adam Savitz, Rosanne Lane, Isaac Nuamah, et al.
Current Medical Research and Opinion
|
June 24, 2011
Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE)
Chris M Kozma, Terra Slaton, Riad Dirani, et al.
International Clinical Psychopharmacology
|
March 3, 2015
Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database
Erica A Voss, Patrick B Ryan, Paul E Stang, et al.
International Clinical Psychopharmacology
|
August 15, 2017
Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority study
Adam J Savitz, Haiyan Xu, Srihari Gopal, et al.
Clinical Pharmacology and Therapeutics
|
August 30, 2020
Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression
Eva G Katz, David Hough, Teodora Doherty, et al.
Page
of 7
Search research articles
Search
Showing results (11-20 of 66) with videos related to
Sort By:
Page
of 7
Journal of Child and Adolescent Psychopharmacology
|
December 20, 2013
An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder
Justine M Kent, David Hough, Jaskaran Singh, et al.
The Journal of Clinical Psychiatry
|
June 21, 2018
Relapse After Antipsychotic Discontinuation in Schizophrenia as a Withdrawal Phenomenon vs Illness Recurrence: A Post Hoc Analysis of a Randomized Placebo-Controlled Study
Robin Emsley, Isaac Nuamah, Srihari Gopal, et al.
Schizophrenia Research
|
December 5, 2009
Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study
David Hough, Srihari Gopal, Ujjwala Vijapurkar, et al.
Schizophrenia Research. Cognition
|
March 11, 2020
Cognitive functioning in adolescents with schizophrenia treated with paliperidone extended-release: 6-Month exploratory analysis from an open-label, single-arm safety study
Gahan Pandina, Isaac Nuamah, Timothy Petersen, et al.
Neuropsychiatric Disease and Treatment
|
October 5, 2013
Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies
Srihari Gopal, Yanning Liu, Larry Alphs, et al.
Journal of Child and Adolescent Psychopharmacology
|
July 29, 2015
Long-Term Safety of Paliperidone Extended Release in Adolescents with Schizophrenia: An Open-Label, Flexible Dose Study
Adam Savitz, Rosanne Lane, Isaac Nuamah, et al.
Current Medical Research and Opinion
|
June 24, 2011
Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE)
Chris M Kozma, Terra Slaton, Riad Dirani, et al.
International Clinical Psychopharmacology
|
March 3, 2015
Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database
Erica A Voss, Patrick B Ryan, Paul E Stang, et al.
International Clinical Psychopharmacology
|
August 15, 2017
Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority study
Adam J Savitz, Haiyan Xu, Srihari Gopal, et al.
Clinical Pharmacology and Therapeutics
|
August 30, 2020
Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression
Eva G Katz, David Hough, Teodora Doherty, et al.
Page
of 7